<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-5669-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZAVEDOS 1MG/ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IDARUBICIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        183.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Zydus Hospira Oncology Private Limited ZHOPL " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Zydus Hospira Oncology Private Limited ZHOPL 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Australia Pty LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01DB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zavedos contains an active ingredient called idarubicin hydrochloride, which belongs to a group of medicines called anthracyclines. Zavedos interferes with ways in which the cells of your body grow and increase in number and is used in the treatment of cancers (chemotherapy).</p><p>&nbsp;</p><p>Zavedos is used in adults and children for the treatment of acute non lymphoblastic leukaemia (ANLL), also referred to as acute myeloid leukaemia (AML).</p><p>&nbsp;</p><p>Zavedos is also used in adults and children as a second line treatment of relapsed acute lymphoblastic leukaemia (ALL).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Zavedos:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had an allergic (hypersensitivity) reaction to</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; idarubicin or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other anthracyclines or anthracenediones.<s> </s></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your liver or kidneys are not working properly.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an infection which is not under control.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had a previous or current history of heart disease.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had a previous or current history of abnormal heart rhythms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had previous or current history of bone marrow depression caused by previous therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have previously been treated with high doses of idarubicin hydrochloride and/ or other anthracyclines or anthracenediones.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast-feeding.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before you are given Zavedos if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suffer from bone marrow depression caused by previous therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have suffered from heart trouble in the past or are presently receiving treatment for this.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had a previous or current history of stomach problems (e.g. ulcer) or any problem with your bowels.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are taking or have recently taken trastuzumab (a medicine used in the treatment of certain cancers). Trastuzumab can take up to 7 months to be removed from the body. As trastuzumab may affect the heart, you should not use Zavedos for up to 7 months after you have stopped taking trastuzumab. If Zavedos is used before this time, then your heart function should be carefully monitored.</p><p>&nbsp;</p><p>Zavedos may affect male fertility. Talk to your doctor about fertility preservation before starting treatment. Both men and women should use effective contraception (see &ldquo;Pregnancy, breast-feeding and fertility&rdquo; section).</p><p>&nbsp;</p><p>If you desire to have children after Zavedos treatment, talk to you doctor about your options.</p><p>&nbsp;</p><p>In these cases, Zavedos might not be a suitable treatment for you, or a reduced dose might have to be used.</p><p><strong>&nbsp;</strong></p><p><strong>Paediatric population</strong></p><p>Babies and children are more at risk to heart problems that may be caused by taking Zavedos. Regular checks of the heart for a longer time will be needed.</p><p>&nbsp;</p><p><strong>Regular checks by your doctor during Zavedos treatment</strong></p><p>Before starting and during treatment you will need regular checks including blood tests.</p><p>Your doctor will be making regular checks of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood, to check for low blood cell counts that may need treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your heart function, as Zavedos can have effects upon this.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your liver and kidneys &ndash; again using blood tests &ndash; to check that Zavedos is not affecting the way they function in a harmful way.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood uric acid levels &ndash; Zavedos may increase uric acid levels in the blood, which might cause gout. Another medicine may be given if your uric acid levels are too high.</p><p>&nbsp;</p><p>You will find more information on some of these effects in section 4.</p><p>&nbsp;</p><p><strong>Other medicines and Zavedos</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, in particular, if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are given medicines or were previously given medicines such as anthracyclines or anthracenediones that have a similar action to Zavedos. They can make the effects of Zavedos stronger.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are using Zavedos with medicines like calcium channel blockers or chemotherapies that have cardiac toxicity.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are receiving radiotherapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are taking oral drugs that prevent blood clots as it will require close monitoring.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are taking a medicine called Cyclosporin A.</p><p>&nbsp;</p><p>You should not take live or live-attenuated vaccines (e.g. yellow fever) because of the risk of serious infection after treatment with chemotherapy.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong><em>Pregnancy</em></strong></p><p>Avoid becoming pregnant while you or your partner is being treated with Zavedos. Zavedos may harm an unborn baby, so it is important to tell your doctor if you think you are pregnant.</p><p>&nbsp;</p><p><u>Contraception in women of childbearing potential</u></p><p>You should always use effective birth control (contraception) whilst receiving Zavedos and for at least 6.5 months after the last dose. Talk to your doctor about birth control methods that are right for you and your partner.</p><p>&nbsp;</p><p><u>Contraception in men</u></p><p>Men should always use effective contraception whilst receiving Zavedos and for at least 3.5 months after the last dose.</p><p>&nbsp;</p><p><strong><em>Breast-feeding</em></strong></p><p>Do not breast-feed whilst receiving Zavedos and for at least 14 days after the last dose, as some of the drug may get into your milk and possibly harm your child.</p><p>&nbsp;</p><p><strong><em>Fertility</em></strong></p><p>Both men and women should seek advice on fertility preservation before treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>It is not known whether Zavedos has an effect on you being able to drive or use any tools or machines. However, special care should be taken if it is essential that you drive or operate machinery while undergoing treatment especially if you are lacking strength or are in a debilitated condition.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zavedos will be given to you by injection into the veins. It should not be given by injection into your spine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will prescribe the required amount (the dose). The dose is decided by taking into account your condition being treated, your height and weight.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From your height and weight the doctor will work out your body surface area; this is necessary because the dose is usually calculated as &quot;X milligrams per square metre&quot; (mg/m<sup>2</sup>), given by injection, on 3 days running.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, your doctor may alter the dose and number of days of treatment depending on your condition and any other treatment you may receive.</p><p>&nbsp;</p><p><strong>If you receive more Zavedos than you should</strong></p><p>High doses can worsen side effects like sores in the mouth or may decrease the number of white blood cells and platelets (these help the blood to clot) in the blood. Should this happen, you may need antibiotics or blood transfusions. Mouth ulcers can be treated to make them less uncomfortable as they heal.</p><p>&nbsp;</p><p>Heart damage can occur when high doses of Zavedos are given. This may not be detected for several weeks, so regular tests may be required during this period.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately </strong>if you experience any of the following symptoms after you have been given this medicine. Although they are very rare, the symptoms can be severe.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions such as feeling dizzy, feverish, breathless with a tight chest, with or without an itchy rash.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pericardium (the fibrous sac surrounding the heart), inflammation of the heart muscle, a disease of the electrical system of the heart.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A condition in which a blood clot that has formed inside a blood vessel or inside the heart.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of the skin, typically over the cheeks or neck.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach ulcer (abdominal pain or burning sensation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hand foot syndrome (tingling, redness, flaking, swelling or small sores on the palms of the hands or soles of the feet).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (low red cells) that can leave you feeling tired and lethargic.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukopenia (low white cells) leading to increased chance of infections with symptoms of raised temperature or fever and chills (like flu).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia (low platelets, these help the blood to clot). You may bruise more easily or bleed more than usual if you hurt yourself.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumour lysis syndrome (the breakdown and release of tumour cell contents), a potentially-life threatening condition, in which you may experience decreased or cloudy urination, weakness, irritability and confusion, vomiting, nausea, muscle cramps or joint discomfort, shortness of breath, irregular heartbeat and seizures. These symptoms can be associated with abnormal laboratory test results (high potassium, uric acid and phosphorous levels and low calcium levels in the blood) that can lead to changes in kidney function and acute renal failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe infections which can occur after treatment with idarubicin alone or in combination with other medicines, and may be fatal.</p><p>&nbsp;</p><p>Very common side effects (may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in number of red blood cells, reduced numbers of white blood cells, abnormally low amount of platelets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A lack or loss of appetite for food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick or being sick, the painful inflammation and ulceration of the mucous membranes lining the digestive tract, diarrhoea, stomach ache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red colouration of urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (rise in temperature).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills.</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase or decrease in heart rate, irregular heart beat/pulse, heart failure, heart attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the vein, swelling (inflammation) of a vein caused by a blood clot.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding from the intestines, pain in the stomach or abdomen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver enzyme elevation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemorrhages.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sensitivity of irradiated skin &lsquo;radiation recall reaction&rsquo;.</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood infection, bacteria in the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancers of blood such as secondary leukaemia or unfavourable leukaemia (acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS)).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful joints due to increased uric acid levels in your blood (gouty arthritis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ECG changes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shock.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the oesophagus, inflammation of the colon.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Darkening of the skin and nails.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive loss of body fluid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spreading of bacterial infection below the skin surface and tissue damage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives.</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke.</p><p>&nbsp;</p><p>Very rare side effects (may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pericardium (the fibrous sac surrounding the heart), defect in the heart&rsquo;s electrical system.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Minor ulceration of the gastric mucosa.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hand foot syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of heart muscle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolism.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flush.</p><p>&nbsp;</p><p>Additional side effects experienced, (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in certain chemicals in the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormally low levels of all blood cells produced by the bone marrow.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Local skin reaction.</p><p>&nbsp;</p><p><strong>Additional side effects in children</strong></p><p>Side effects seen in children are similar to those seen for adults. Children have a higher risk for heart problems that could be caused by taking Zavedos.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zavedos is for single use only. It should be used immediately after opening and any unused portion should be discarded.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the vial label and carton after EXP. The expiry date refers to the last date of that month.</p><p>&nbsp;</p><p>The shelf life is 3 years.</p><p>&nbsp;</p><p>Zavedos should be stored in a refrigerator (2&deg;C -8&deg;C) and the vial kept in the outer carton in order to protect from light. Do not freeze.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is idarubicin hydrochloride. Each mL of solution for injection contains 1 mg idarubicin hydrochloride.</p><p>&nbsp;</p><p>Each vial of 5 mL of solution for injection contains 5 mg of idarubicin hydrochloride.</p><p>Each vial of 10 mL of solution for injection contains 10 mg of idarubicin hydrochloride.</p><p>&nbsp;</p><p>The other ingredients are glycerol, hydrochloric acid and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zavedos is supplied as a clear orange-red aqueous solution in glass vials which are closed with a rubber stopper and sealed with an aluminium cap with plastic flip off top. The vials are packed singly in cartons. 

Zavedos is available in 5 ml, and 10 mL vials. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation</strong> <strong>Holder</strong></p><p>Pfizer Australia Pty LTD, 17 151 Clarence Street Sydney NSW 2000, Australia</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Zydus Hospira Oncology Private Limited (ZHOPL), India</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زافيدوس على مكون فعال يسمى هيدروكلوريد إيداروبيسين ينتمي إلى مجموعة من الأدوية تسمى مركبات الأنثراسيكلين. يتداخل زافيدوس مع الطرق التي تنمو بها خلايا جسمك وتتكاثر، ويُستخدم في علاج السرطانات (العلاج الكيميائي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم زافيدوس في البالغين والأطفال لعلاج&nbsp; سرطان الدم اللالمفاوي الحاد و سرطان الدم النخاعي الحاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم زافيدوس أيضًا في البالغين والأطفال كخط علاج ثانٍ لابيضاض الدم الأرومي الليمفاوي الحاد (ALL) المنتكس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>موانع استعمال زافيدوس:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بتفاعل حساسية (فرط حساسية) تجاه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيداروبيسين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركبات الأنثراسيكلين أو الأنثراسينيديون الأخرى.<s> </s></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان كبدك أو كليتاك لا تعملان كما ينبغي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى لم يتم التحكم بها بعد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ سابق أو حالٍ من الإصابة بأمراض القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ سابق أو حالٍ من الإصابة باضطراب ضربات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ سابق أو حالٍ من الإصابة بكبت نخاع العظم تسبب فيه علاج سابق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد تم علاجك في السابق باستخدام جرعات عالية من هيدروكلوريد إيداروبيسين و/أو مركبات الأنثراسيكلين أو الأنثراسينيديون الأخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال زافيدوس</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل أن يتم إعطاؤك زافيدوس إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من كبت نخاع العظم سببه علاج سابق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد عانيت في الماضي من مشكلة في القلب، أو كنت تتلقى حاليًا علاجًا لهذه المشكلة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك تاريخ سابق أو حالٍ من الإصابة بمشكلات المعدة (مثل القرحة) أو أي مشكلة في أمعائك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في هذه الحالات، قد لا يكون زافيدوس علاجًا ملائمًا لك، أو قد تكون هناك حاجة للجوء إلى جرعة مخفضة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أو تناولت مؤخرًا تراستوزوماب (دواء يُستخدم في علاج بعض أنواع السرطانات). يمكن لتراستوزوماب أن يستغرق مدة تصل إلى ٧ أشهر حتى يتخلص منه الجسم. نظرًا لأن تراستوزوماب قد يؤثر على القلب، ينبغي ألا تستخدم زافيدوس لمدة تصل إلى ٧ أشهر بعد توقفك عن تناول تراستوزوماب. إذا استخدم زافيدوس قبل هذه المدة، ينبغي حينئذ أن تُراقب وظائف القلب لديك بدقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر زافيدوس على الخصوبة لدى الذكور. تحدث إلى طبيبك عن الحفاظ على الخصوبة قبل البدء في العلاج. ينبغي لكل من السيدات والرجال استخدام وسيلة فعالة لمنع الحمل (انظر قسم &quot;الحمل والرضاعة والخصوبة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت ترغب في إنجاب الأطفال بعد العلاج بزافيدوس، فتحدث إلى طبيبك عن الخيارات المتاحة أمامك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فئة الأطفال</strong></p><p dir="RTL">يعتبر الرضع والأطفال أكثر عرضة لخطر الإصابة بمشكلات القلب التي قد يسببها تناول زافيدوس. لذا سيلزم إجراء فحوصات منتظمة للقلب لمدة أطول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الفحوصات المنتظمة التي يجريها طبيبك أثناء العلاج باستخدام زافيدوس</strong></p><p dir="RTL">ستحتاج قبل بدء العلاج وأثناء تلقيه إلى الخضوع لفحوصات منتظمة بما في ذلك فحوصات الدم.</p><p dir="RTL">سيجري طبيبك فحوصات منتظمة لـ:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دمك، للتحقق من عدم انخفاض تعداد خلايا دمك، الأمر الذي قد يتطلب العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف قلبك، لأن زافيدوس قد يكون له آثار عليها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبدك وكليتيك، أيضًا باستخدام فحوصات الدم، للتأكد من أن زافيدوس لا يؤثر بشكل مؤذٍ على الطريقة التي يعملان بها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات حمض اليوريك في الدم، حيث يمكن أن يزيد زافيدوس من مستويات حمض اليوريك في الدم، مما قد يتسبب في الإصابة بالنقرس. قد يتم إعطاؤك دواءً آخر إذا كانت مستويات حمض اليوريك لديك مرتفعة للغاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستجد المزيد من المعلومات حول بعض هذه الآثار في القسم ٤.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، وبصفة خاصة، إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان يتم إعطاؤك أو تم إعطاؤك فيما سبق أدوية مثل مركبات الأنثراسيكلين أو الأنثراسينيديون التي لها تأثير مشابه لزافيدوس. لأنها يمكن أن تزيد من شدة آثار زافيدوس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تستخدم زافيدوس بالتزامن مع أدوية مثل حاصرات قنوات الكالسيوم أو العلاجات الكيميائية التي تسبب السمية القلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتلقى العلاج الإشعاعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول عقاقير عن طريق الفم تمنع تكوّن الجلطات الدموية لأن في هذه الحالة ستلزم مراقبة حالتك عن كثب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول دواءً يسمى سيكلوسبورين أ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي ألا تتناول اللقاحات الحية أو اللقاحات الحية الموهنة (مثل لقاح الحمى الصفراء) بسبب وجود احتمال للإصابة بعدوى خطيرة بعد العلاج باستخدام العلاج الكيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الحمل</em></strong></p><p dir="RTL">تجنبي الحمل أثناء خضوعكِ أو خضوع زوجكِ للعلاج باستخدام زافيدوس. قد يلحق زافيدوس الأذى بالأجنة، لذا من المهم أن تخبري طبيبكِ إذا كنتِ تعتقدين أنكِ حامل<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>وسائل منع الحمل في حالة السيدات في سن الإنجاب</u></p><p dir="RTL">ينبغي لكِ دائمًا استخدام وسيلة فعالة لتحديد النسل (وسائل منع الحمل) أثناء تلقي زافيدوس ولمدة ٦٬٥ أشهر على الأقل بعد تلقي آخر جرعة. تحدثي إلى طبيبكِ عن وسائل تحديد النسل المناسبة لكِ ولزوجكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>وسائل منع الحمل في حالة الرجال</u></p><p dir="RTL">ينبغي للرجال دائمًا استخدام وسيلة فعالة لمنع الحمل أثناء تلقي زافيدوس ولمدة ٣٬٥ أشهر على الأقل بعد تلقي آخر جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الرضاعة الطبيعية</em></strong></p><p dir="RTL">لا تقومي بالرضاعة الطبيعية أثناء تلقيكِ زافيدوس ولمدة ١٤ يومًا على الأقل بعد تلقي آخر جرعة، حيث إن بعض العقار قد ينتقل إلى لبن الثدي الخاص بكِ ويحتمل أن يؤذي طفلكِ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>الخصوبة</em></strong></p><p dir="RTL">ينبغي لكل من الرجال والسيدات طلب المشورة فيما يتعلق بالحفاظ على الخصوبة قبل العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زافيدوس على القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس معروفًا إذا ما كان لزافيدوس أثر على قدرتك على القيادة أو استخدام أي أدوات أو آلات أم لا. ومع ذلك، ينبغي توخي الحذر بشكل خاص إذا كان من الضروري أن تقوم بالقيادة أو تشغيل آلات أثناء الخضوع للعلاج خاصةً إذا كانت تنقصك القوة أو إذا كنت تشعر بحالة من الضعف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيُعطى زافيدوس إليك عن طريق الحقن في الوريد. ينبغي عدم إعطائه عن طريق الحقن في عمودك الفقري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيصف لك طبيبك الكمية المطلوبة (الجرعة). تُحدد الجرعة بالأخذ في الاعتبار حالتك التي يتم علاجها وطولك ووزنك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيحدد الطبيب مساحة سطح جسمك عن طريق وزنك وطولك؛ وهذا ضروري لأنه عادةً ما يتم حساب الجرعة بحيث تمثل &quot;X مليجرامات لكل متر مربع&quot;. (ملجم/متر<sup>٢</sup>)، تُعطى عن طريق الحقن لثلاثة أيام متتالية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومع ذلك، قد يقوم طبيبك بتغيير الجرعة وعدد أيام العلاج وفقًا لحالتك وأي علاج آخر قد تتلقاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زافيدوس</strong></p><p dir="RTL">يمكن أن تسبب الجرعات العالية تفاقم الآثار الجانبية مثل التقرحات في الفم أو قد تقلل من عدد خلايا الدم البيضاء والصفيحات الدموية (التي تساعد الدم على التخثر) في الدم. إذا حدث هذا، فقد تحتاج إلى تلقي مضادات حيوية أو عمليات نقل دم. يمكن علاج قرح الفم لجعلها أقل إزعاجًا أثناء التئامها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يحدث تلف قلبي عند إعطاء جرعات عالية من زافيدوس. وقد لا يتم اكتشاف هذا لعدة أسابيع، لذا قد يلزم إجراء اختبارات بشكل منتظم أثناء هذه الفترة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور </strong>إذا أصبت بأي من الأعراض التالية بعد إعطائك هذا الدواء. على الرغم من أن هذه الأعراض نادرة جدًا، فإنها يمكن أن تكون شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية مثل الشعور بالدوار، الحمى، عدم القدرة على التنفس مع ضيق الصدر، مع أو بدون الطفح الجلدي المثير للحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب التأمور (الكيس الليفي المحيط بالقلب)، التهاب عضلة القلب، مرض يصيب النظام الكهربي للقلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تتكوّن فيها جلطة دموية داخل أحد الأوعية الدموية أو داخل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد، عادةً في الخدود أو الرقبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة المعدة (ألم في المعدة أو إحساس بالحرقة فيها).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة اليد والقدم (التنميل، أو الاحمرار، أو التقشر، أو التورم، أو وجود تقرحات صغيرة على راحة اليدين أو باطن القدمين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (انخفاض عدد خلايا الدم الحمراء) الذي يمكن أن يتسبب في شعورك بالتعب والخمول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الكريات البيضاء (انخفاض عدد خلايا الدم البيضاء) مما يؤدي إلى زيادة فرصة الإصابة بعدوى مع وجود أعراض ارتفاع درجة الحرارة أو الحمى والقشعريرة (تشبه أعراض الإنفلونزا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الصفيحات الدموية (انخفاض عدد الصفيحات الدموية التي تساعد الدم على التخثر). قد تصاب بالتكدم بسهولة أكبر أو تنزف بشكل أكثر من المعتاد إذا تعرضت للأذى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة تحلل الورم (انحلال خلايا الورم وخروج محتوياتها)، حالة يحتمل أن تكون مهددة للحياة، حيث قد تصاب خلالها بانخفاض كمية البول أو تكدره، والضعف، والتهيج والارتباك، والقيء، والغثيان، والشد العضلي أو الشعور بانزعاج في المفاصل، وضيق التنفس، وعدم انتظام ضربات القلب، والنوبات. يمكن ربط هذه الأعراض باختلال في نتائج الاختبارات المعملية (ارتفاع مستويات البوتاسيوم وحمض اليوريك والفسفور وانخفاض مستويات الكالسيوم في الدم) قد يؤدي إلى حدوث تغيرات في وظائف الكلى والإصابة بفشل كلوي حاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى شديدة، يمكن أن تكون مميتة، بعد العلاج باستخدام إيداروبيسين بمفرده أو بالتزامن مع أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء، انخفاض عدد خلايا الدم البيضاء، انخفاض غير طبيعي في عدد الصفيحات الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو فقدان الشهية للطعام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور برغبة في التقيؤ أو التقيؤ بالفعل، التهاب وتقرح مؤلمان في الأغشية المخاطية المبطنة للقناة الهضمية، الإسهال، ألم المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار لون البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (ارتفاع درجة الحرارة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو انخفاض معدل نبضات القلب، عدم انتظام ضربات/نبضات القلب، فشل القلب، أزمة قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد، تورم (التهاب) أحد الأوردة بسبب تكوّن جلطة دموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الأمعاء، ألم في المعدة أو البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات إنزيمات الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، الحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد الذي تعرض للإشعاع &quot;تفاعل استرجاع الإشعاع&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الدم، وجود بكتيريا في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطانات الدم مثل ابيضاض الدم الثانوي أو ابيضاض الدم غير المبشر (ابيضاض الدم النقوي الحاد أو متلازمة خلل التنسج النقوي (MDS)).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل نتيجة لزيادة مستويات حمض اليوريك في دمك (التهاب المفاصل النقرسي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في مخططات رسم القلب (ECG).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصدمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المريء، التهاب القولون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دكنة لون الجلد والأظافر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان مفرط لسوائل الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار العدوى البكتيرية إلى طبقات ما بعد سطح الجلد وتلف النسيج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزمة قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية النادرة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية النادرة جدًا (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠٠ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية خطير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب التأمور (الكيس الليفي المحيط بالقلب)، خلل في النظام الكهربي للقلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرح طفيف في الغشاء المخاطي المعدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة اليد والقدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب عضلة القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانصمام الخثاري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية إضافية أصيب بها المرضى (لا يمكن تقدير معدل تكرارها من البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في بعض المواد الكيميائية في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض غير طبيعي في مستويات جميع خلايا الدم التي ينتجها نخاع العظم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية موضعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية إضافية في الأطفال</strong></p><p dir="RTL">الأعراض الجانبية التي تمت ملاحظتها في الأطفال مشابهة لتلك التي تمت ملاحظتها في البالغين. إن الأطفال معرضون بنسبة أعلى لخطر الإصابة بمشكلات القلب التي يمكن أن يسببها تناول زافيدوس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>إ</strong>ذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عبر نظام الإبلاغ الوطني. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ<strong> </strong>عن أي أثر جانبي (آثار جانبية):</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: ١٩٩٩٩</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL"><strong><em>&nbsp;</em></strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زافيدوس مخصص للاستخدام لمرة واحدة فقط. وينبغي أن يُستخدم فورًا بعد الفتح وأن يتم التخلص من أي كمية غير مستخدمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق القارورة والعبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">صلاحية المستحضر ٣ سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تخزين زافيدوس في الثلاجة (من درجتين مئويتين إلى ٨ درجات مئوية) وحفظ القارورة في العبوة الكرتونية الخارجية لحمايتها من الضوء. لا تقم بالتجميد.</p><p dir="RTL">لا تتخلص من أي دواء عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المادة الفعالة هي هيدروكلوريد إيداروبيسين. يحتوي كل مل من المحلول المخصص للحقن على ١ ملجم من هيدروكلوريد إيداروبيسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل قارورة سعة ٥ مل من المحلول المخصص للحقن على ٥ ملجم من هيدروكلوريد إيداروبيسين.</p><p dir="RTL">تحتوي كل قارورة سعة ١٠ مل من المحلول المخصص للحقن على ١٠ ملجم من هيدروكلوريد إيداروبيسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي جليسرول، وحمض الهيدروكلوريك، وماء للحقن</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يُورَّد زافيدوس في صورة محلول مائي صافٍ لونه برتقالي إلى أحمر في قوارير من الزجاج مغلقة بسدادة مطاطية ومحكمة الغلق بغطاء من الألومنيوم مع غطاء بلاستيكي يُفتح لأعلى. تتم تعبئة القوارير في عبوات كرتونية تحتوي كل منها على قارورة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتاح زافيدوس في قوارير بحجم ٥ مل، و١٠ مل.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Australia Pty LTD, 17 151 Clarence Street Sydney NSW 2000, Australia</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجهة المصنعة:</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Zydus Hospira Oncology Private Limited (ZHOPL), India</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/تشرين الثاني ٢٠٢٣.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zavedos 1mg/mL Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of solution contains 1 mg of idarubicin hydrochloride. 

Each vial of 5 mL of solution contains 5 mg of idarubicin hydrochloride.
Each vial of 10 mL of solution contains 10 mg of idarubicin hydrochloride.

	For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Injection

Orange-red, clear solution, sterile, and pyrogenic-free.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p>For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.</p><p>&nbsp;</p><p>For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>For first line treatment of acute myeloid-leukaemia (AML), in combination with cytarabine, for remission induction.</p><p>&nbsp;</p><p>For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).</p><p>&nbsp;</p><p>Zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>Dosage is calculated on the basis of body surface area.</p><p>&nbsp;</p><p><u>Acute myeloid leukaemia (AML)</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>12 mg/m<sup>2</sup>/day i.v. daily for 3 days in combination with cytarabine.</p><p>or</p><p>8 mg/m<sup>2</sup>/day i.v. daily for 5 days with/without combination.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>10-12&nbsp;mg/m<sup>2</sup>/day i.v. daily for 3 days in combination with cytarabine.</p><p>&nbsp;</p><p><u>Acute lymphoblastic leukaemia (ALL)</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>As single agent in ALL<em> </em>the suggested dose in adults is 12 mg/m<sup>2</sup>/day i.v. daily for 3 days.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>10 mg/m<sup>2</sup>/day i.v. daily for 3 days, as a single agent.</p><p>&nbsp;</p><p>NOTE: These are general guidelines. Refer to individual protocols for exact dosage.</p><p>&nbsp;</p><p>All of these dosage schedules should, however, take into account the haematological status of the patient and the dosages of other cytotoxic drugs when used in combination.</p><p>&nbsp;</p><p>Administration of a second course should be delayed in patients who develop severe mucositis until recovery from this toxicity has occurred and a dose reduction of 25% is recommended.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For intravenous use only (See Section 6.6 Special precautions for disposal and handling).</p><p>&nbsp;</p><p>Not for intrathecal use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to idarubicin or to any of the excipients listed in section 6.1, other anthracyclines or anthracenediones
•	Severe hepatic impairment
•	Severe renal impairment
•	Uncontrolled infections
•	Severe cardiomyopathy 
•	Recent myocardial infarction
•	Severe arrhythmias
•	Persistent myelosuppression
•	Previous treatment with maximum cumulative doses of idarubicin hydrochloride and/or other anthracyclines and anthracenediones (see section 4.4)
•	Breast-feeding should be stopped during drug therapy (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Idarubicin should be administered only under the supervision of physicians experienced in the use of cytotoxic chemotherapy.&nbsp;</p><p>&nbsp;</p><p>This ensures that immediate and effective treatment of severe complications of the disease and/or its treatment (e.g. haemorrhage, overwhelming infections) may be carried out.</p><p>&nbsp;</p><p>Patients should recover from acute toxicities of prior cytotoxic treatment (such as stomatitis, neutropenia, thrombocytopenia, and generalized infections) before beginning treatment with idarubicin hydrochloride.</p><p>&nbsp;</p><p><u>Haematological toxicity</u></p><p>Idarubicin is a potent bone marrow suppressant. Severe myelosuppression will occur in all patients given a therapeutic dose of this agent.</p><p>&nbsp;</p><p>Haematological profiles should be assessed before and during each cycle of therapy with idarubicin, including differential white blood cell (WBC) counts.</p><p>&nbsp;</p><p>A dose-dependent, reversible leukopenia and/or granulocytopenia (neutropenia) is the predominant manifestation of idarubicin haematologic toxicity and is the most common acute dose limiting toxicity of the drug.</p><p>&nbsp;</p><p>Leukopenia and neutropenia are usually severe, thrombocytopenia and anaemia may also occur. Neutrophil and platelet counts usually reach their nadir 10 to 14 days after drug administration; however, cell counts generally return to normal levels during the third week.</p><p>&nbsp;</p><p>During the phase of severe myelosuppression, deaths due to infections and/or haemorrhages have been reported.</p><p>&nbsp;</p><p>Clinical consequences of severe myelosuppression include fever, infections, sepsis/septicaemia, septic shock, haemorrhage, tissue hypoxia or death. If febrile neutropenia occurs, treatment with an i.v. antibiotic is recommended.</p><p>&nbsp;</p><p><u>Secondary leukaemia</u></p><p>Secondary leukaemia, with or without a preleukaemic phase, has been reported in patients treated with anthracyclines, including idarubicin. Secondary leukaemia is more common when such drugs are given in combination with DNA-damaging antineoplastic agents, when patients have been heavily pre-treated with cytotoxic drugs, or when doses of the anthracyclines have been escalated. These leukaemias can have a 1 to 3 year latency period.</p><p>&nbsp;</p><p><u>Cardiac function</u></p><p>Cardiotoxicity is a risk of anthracycline treatment that may be manifested by early (i.e. acute) or late (i.e. delayed) events.</p><p>&nbsp;</p><p><em>Early (i.e. acute) events</em></p><p>Early cardiotoxicity of idarubicin consists mainly of sinus tachycardia and/or electrocardiogram (ECG) abnormalities, such as non-specific ST-T wave changes. Tachyarrhythmias, including premature ventricular contractions and ventricular tachycardia, bradycardia, as well as atrioventricular and bundle-branch block have also been reported. These effects do not usually predict subsequent development of delayed cardiotoxicity, are rarely of clinical importance, and are generally not a reason for the discontinuation of idarubicin treatment.</p><p>&nbsp;</p><p><em>Late (i.e. delayed) events</em></p><p>Delayed cardiotoxicity usually develops late in the course of therapy or within 2 to 3 months after treatment termination, but later events, several months to years after completion of treatment have also been reported. Delayed cardiomyopathy is manifested by reduced left ventricular ejection fraction (LVEF) and/or signs and symptoms of congestive heart failure (CHF) such as dyspnoea, pulmonary oedema, dependent oedema, cardiomegaly, hepatomegaly, oliguria, ascites, pleural effusion, and gallop rhythm. Subacute effects such as pericarditis/myocarditis have also been reported. Life-threatening CHF is the most severe form of anthracycline-induced cardiomyopathy and represents the cumulative dose-limiting toxicity of the drug.</p><p>&nbsp;</p><p>Cumulative dose limits for i.v. or oral idarubicin hydrochloride have not been defined. However, idarubicin-related cardiomyopathy was reported in 5% of patients who received cumulative i.v. doses of 150 to 290 mg/m<sup>2</sup>. Available data on patients treated with oral idarubicin hydrochloride total cumulative doses up to 400 mg/m<sup>2</sup> suggest a low probability of cardiotoxicity.</p><p>&nbsp;</p><p>Cardiac function should be assessed before patients undergo treatment with idarubicin and must be monitored throughout therapy to minimize the risk of incurring severe cardiac impairment. The risk may be decreased through regular monitoring of LVEF during the course of treatment with prompt discontinuation of idarubicin at the first sign of impaired function. The appropriate quantitative method for repeated assessment of cardiac function (evaluation of LVEF) includes Multiple Gated Acquisition (MUGA) scan or echocardiography (ECHO). A baseline cardiac evaluation with an ECG and either a MUGA scan or an ECHO is recommended, especially in patients with risk factors for increased cardiotoxicity. Repeated MUGA or ECHO determinations of LVEF should be performed, particularly with higher, cumulative anthracycline doses. The technique used for assessment should be consistent throughout follow-up.</p><p>&nbsp;</p><p>Risk factors for cardiac toxicity include active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, and concomitant use of drugs with the ability to suppress cardiac contractility or cardiotoxic drugs (e.g. trastuzumab). Anthracyclines including idarubicin should not be administered in combination with other cardiotoxic agents unless the patient&rsquo;s cardiac function is closely monitored (see section 4.5). Patients receiving anthracyclines after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, may also be at an increased risk of developing cardiotoxicity. The reported half-life of trastuzumab is variable. The substance may persist in circulation for up to 7 months. Therefore, physicians should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If this is not possible, the patient&rsquo;s cardiac function should be monitored carefully.</p><p><strong><em>&nbsp;</em></strong></p><p>Cardiac function monitoring must be particularly strict in patients receiving high cumulative doses and in those with risk factors. However, cardiotoxicity with idarubicin may occur at lower cumulative doses whether or not cardiac risk factors are present.</p><p>&nbsp;</p><p>In infants and children there appears to be a greater susceptibility to anthracycline induced cardiac toxicity, and a long-term periodic evaluation of cardiac function has to be performed.</p><p>&nbsp;</p><p>It is probable that the toxicity of idarubicin and other anthracyclines or anthracenediones is additive.</p><p>&nbsp;</p><p><u>Hepatic and renal function</u></p><p>Since hepatic and/or renal function impairment can affect the disposition of idarubicin, liver and kidney function should be evaluated with conventional clinical laboratory tests (using serum bilirubin and serum creatinine as indicators) prior to, and during, treatment. In a number of Phase III clinical trials, treatment was contraindicated if bilirubin and/or creatinine serum levels exceeded 2.0 mg %. With other anthracyclines a 50% dose reduction is generally used if bilirubin levels are in the range 1.2-2.0 mg %.</p><p>&nbsp;</p><p><u>Gastrointestinal</u></p><p>Idarubicin is emetogenic. Mucositis (mainly stomatitis, less often oesophagitis) generally appears early after drug administration and, if severe, may progress over a few days to mucosal ulcerations. Most patients recover from this adverse event by the third week of therapy.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Occasionally, episodes of serious gastrointestinal events (such as perforation or bleeding) have been observed in patients receiving oral idarubicin who had acute leukaemia or a history of other pathologies or had received medications known to lead to gastrointestinal complications. In patients with active gastrointestinal disease with increased risk of bleeding and/or perforation, the physician must balance the benefit of oral idarubicin therapy against the risk.</p><p>&nbsp;</p><p><u>Effects at site of injection</u></p><p>Phlebosclerosis may result from an injection into a small vessel or from previous injections into the same vein. Following the recommended administration procedures may minimise the risk of phlebitis/thrombophlebitis at the injection site (See Section 6.6 Special precautions for disposal and handling).</p><p>&nbsp;</p><p><u>Extravasation</u></p><p>Extravasation of idarubicin during intravenous injection may cause local pain, severe tissue lesions (vesication, severe cellulitis), and necrosis. Should signs or symptoms of extravasation occur during intravenous administration of idarubicin, the drug infusion should be immediately stopped (See Section 6.6 Special precautions for disposal and other handling).</p><p>&nbsp;</p><p>In cases of extravasation dexrazoxane can be used to prevent or reduce tissue injury.</p><p>&nbsp;</p><p><u>Tumour lysis syndrome</u></p><p>Idarubicin may induce hyperuricaemia as a consequence of the extensive purine catabolism that accompanies rapid drug-induced lysis of neoplastic cells (&lsquo;tumour lysis syndrome&rsquo;). Blood uric acid levels, potassium, calcium phosphate, and creatinine should be evaluated after initial treatment. Hydration, urine alkalinisation, and prophylaxis with allopurinol to prevent hyperuricaemia may minimize potential complications of tumour lysis syndrome.</p><p>&nbsp;</p><p><u>Immunosuppressant effects/increased susceptibility to infections</u><strong><em> </em></strong></p><p>Administration of live or live-attenuated vaccines (like yellow fever) in patients immunocompromised by chemotherapeutic agents including idarubicin, may result in serious or fatal infections. Vaccination with a live vaccine should be avoided in patients receiving idarubicin. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p><p>&nbsp;</p><p><u>Reproductive system</u></p><p>Idarubicin can cause genotoxicity. Male and female patients treated with idarubicin hydrochloride are advised to adopt effective contraceptive measures during therapy and for a period after treatment.</p><p>Men treated with idarubicin hydrochloride are advised, if appropriate and available, to seek advice on sperm preservation due to the possibility of irreversible infertility caused by the therapy (see section 4.6). Patients desiring to have children after completion of therapy should be advised to discuss with an appropriate specialist first.</p><p>&nbsp;</p><p><u>Other</u></p><p>As with other cytotoxic agents, thrombophlebitis and thromboembolic phenomena, including pulmonary embolism have been coincidentally reported with the use of idarubicin.</p><p>&nbsp;</p><p>The product may cause a red colouration of the urine for 1-2 days after administration and patients should be advised of this fact.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Idarubicin is a potent myelosuppressant and combination chemotherapy regimens including other agents with similar action may be expected to induce additive myelosuppressive effects (see section 4.4).</p><p>&nbsp;</p><p>Changes in hepatic or renal function induced by concomitant therapies may affect idarubicin metabolism, pharmacokinetics and therapeutic efficacy and/ or toxicity (see section 4.4).</p><p>&nbsp;</p><p>The use of idarubicin in combination chemotherapy with other potentially cardiotoxic drugs, as well as the concomitant use of other cardioactive compounds (e.g. calcium channel blockers), requires monitoring of cardiac function throughout treatment. An additive myelosuppressant effect may occur when radiotherapy is given concomitantly or within 2-3 weeks prior to treatment with idarubicin.</p><p>&nbsp;</p><p>Concomitant use of live attenuated vaccines (e.g. yellow fever) is not recommended, due to a risk of possibly fatal systemic disease. The risk is increased in subjects who are already immunosuppressed by their underlying disease. An inactivated vaccine should be used if available.</p><p>&nbsp;</p><p>At combination of oral anticoagulants and anticancer chemotherapy, increased frequency of the INR (International Normalised Ratio) monitoring is recommended, since the risk for an interaction cannot be excluded.</p><p>&nbsp;</p><p>Cyclosporin A: The co-administration of cyclosporin A as a single chemosensitizer significantly increased idarubicin AUC (1.78-fold) and idarubicinol AUC (2.46-fold) in patients with acute leukaemia. The clinical significance of this interaction is unknown. A dosage adjustment may be necessary in some patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited amount of data from the use of idarubicin in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Idarubicin should not be used during pregnancy unless the potential benefit justifies the potential risk to the foetus. The patient should be informed of the potential hazard to the foetus.</p><p>&nbsp;</p><p><u>Women of childbearing potential / Contraception in males and females</u></p><p>Women of childbearing potential should be advised not to become pregnant and to use effective contraception during treatment with idarubicin and for at least 6.5 months after the last dose. Men with female partners of childbearing potential should be advised to use effective contraception during treatment with idarubicin and for at least 3.5 months after the last dose (see section 4.4).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is not known whether idarubicin or its metabolites are excreted in human milk. As other anthracyclines are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from idarubicin, women should be advised not to breastfeed during treatment with idarubicin and for at least 14 days after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Idarubicin can induce chromosomal damage in human spermatozoa. Both men and women should seek advice on fertility preservation before treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of idarubicin on the ability to drive or use machinery has not been systematically evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The frequencies of undesirable effects are based on the following categories:</p><p>&nbsp;</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:546px"><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Infections</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Sepsis, septicaemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Secondary leukaemia (acute myeloid leukaemia and myelodysplastic syndrome)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Anaemia, severe leukopenia and neutropenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known</em></p></td><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em></p></td><td style="vertical-align:top"><p>Anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Dehydration</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Hyperuricaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known</em></p></td><td style="vertical-align:top"><p>Tumour Lysis Syndrome</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>Cerebral haemorrhages</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Bradycardia, sinus tachycardia, tachyarrhythmia, asymptomatic reduction of left ventricular ejection fraction, congestive heart failure, cardiomyopathies (see section 4.4 for associated signs and symptoms)</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>ECG abnormalities (e.g. nonspecific ST segment changes), myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em></p></td><td style="vertical-align:top"><p>Pericarditis, myocarditis, atrioventricular and bundle branch block</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Local phlebitis, thrombophlebitis, haemorrhages</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Shock</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em></p></td><td style="vertical-align:top"><p>Thromboembolism, flush</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Nausea, vomiting, mucositis/stomatitis, diarrhoea, abdominal pain or burning sensation</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Gastrointestinal tract bleeding, bellyache</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Oesophagitis, colitis (including severe enterocolitis / neutropenic enterocolitis with perforation)</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em></p></td><td style="vertical-align:top"><p>Gastric erosions or ulcerations</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Elevation of the liver enzymes and bilirubin</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Rash, itch, hypersensitivity of irradiated skin (&lsquo;radiation recall reaction&rsquo;)</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Skin and nail hyperpigmentation, urticaria, cellulitis (this event can be severe), tissue necrosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em></p></td><td style="vertical-align:top"><p>Acral erythema</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known</em></p></td><td style="vertical-align:top"><p>Local reaction</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Red coloration of the urine for 1-2 days after the treatment</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Fever, headache, chills</p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><u>Haematopoietic system</u></p><p>Pronounced myelosuppression is the most severe adverse effect of idarubicin treatment. However, this is necessary for the eradication of leukaemic cells (see section 4.4).</p><p>&nbsp;</p><p><u>Cardiotoxicity</u></p><p>Life-threatening CHF is the most severe form of anthracycline-induced cardiomyopathy and represents the cumulative dose-limiting toxicity of the drug (see section 4.4).</p><p>&nbsp;</p><p><u>Gastrointestinal</u></p><p>Stomatitis and in severe cases ulceration of mucosa, dehydration caused by severe vomiting and diarrhoea; risk of perforation of colon etc.</p><p>&nbsp;</p><p><u>Administration site</u></p><p>Phlebitis/thrombophlebitis and prevention measures discussed in section 4.2; unintended paravenous infiltrates may cause pain, severe cellulites and tissue necrosis.</p><p>&nbsp;</p><p><u>Other adverse reactions: hyperuricaemia </u></p><p>Prevention of symptoms by hydration, urine alkalinisation, and prophylaxis with allopurinol may minimise potential complications of tumour lysis syndrome.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Undesirable effects are similar in adults and children except a greater susceptibility to anthracycline-induced cardiac toxicity of children (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>Other </strong><strong>GCC</strong><strong> States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Very high doses of idarubicin may be expected to cause acute myocardial toxicity within 24&nbsp;hours and severe myelosuppression within one to two weeks. Delayed cardiac failure has been seen with the anthracyclines up to several months after the overdose. Patients treated with oral idarubicin should be observed for possible gastrointestinal haemorrhage and severe mucosal damage.<em> </em><em> </em><em> </em></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anthracyclines and related substances</p><p>ATC Code: L01DB06</p><p>&nbsp;</p><p>Idarubicin is a DNA intercalating anthracycline which interacts with the enzyme topoisomerase II and has an inhibitory effect on nucleic acid synthesis.</p><p>&nbsp;</p><p>The modification of position 4 of the anthracycline structure gives the compound a high lipophilicity which results in an increased rate of cellular uptake compared with doxorubicin and daunorubicin.</p><p>&nbsp;</p><p>Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes. Studies <em>in-vitro</em> on human and murine anthracycline-resistant cells have shown a lower degree of cross-resistance for idarubicin compared with doxorubicin and daunorubicin. Cardiotoxicity studies in animals have indicated that idarubicin has a better therapeutic index than daunorubicin and doxorubicin. The main metabolite, idarubicinol, has shown, <em>in-vitro </em>and<em> in-vivo,</em> antitumoural activity in experimental models. In the rat, idarubicinol administered at the same doses as the parent drug, is clearly less cardiotoxic than idarubicin.</p><p>&nbsp;</p><p><em>In vitro</em> studies have shown plasma protein binding of at least 95% for this product. This fact should be borne in mind when considering its use in combination with other drugs.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In adults, following oral administration of 10 to 60&nbsp;mg/m<sup>2</sup> idarubicin, idarubicin was rapidly absorbed with the maximum plasma concentrations of 4-12.65&nbsp;ng/mL achieved in 1 to 4&nbsp;hours after dosing. The terminal half<strong>-</strong>life was 12.7&plusmn;6.0&nbsp;hrs (mean&plusmn;SD).<em> </em>Following intravenous administration of idarubicin in adults, the terminal half-life was 13.9&plusmn;5.9&nbsp;hrs, similar to that observed after the oral administration.</p><p>&nbsp;</p><p>After i.v. administration, idarubicin is extensively metabolised to an active metabolite, idarubicinol, which is slowly eliminated with a plasma T<sub>&frac12;</sub> ranging between 41-69 hours).&nbsp; The drug is eliminated by biliary and renal excretion, mostly in the form or idarubicinol.</p><p>&nbsp;</p><p>Studies of cellular (nucleated blood and bone marrow cells) in leukaemic patients have shown that peak cellular idarubicin concentrations are reached a few minutes after injection.&nbsp;</p><p>&nbsp;</p><p>Idarubicin and idarubicinol concentrations in nucleated blood and bone marrow cells are more than a hundred times the plasma concentrations. Idarubicin disappearance rates in plasma and cells were comparable, with a terminal half-life of about 15 hours. The terminal half-life of idarubicinol in cells was about 72 hours.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Pharmacokinetic measurements in 7&nbsp;paediatric patients receiving intravenous idarubicin hydrochloride in doses ranging from 15 to 40&nbsp;mg/m<sup>2</sup> over the 3 days of treatment, showed a median idarubicin half-life of 8.5&nbsp;hrs (range: 3.6-26.4&nbsp;hrs). The active metabolite, idarubicinol, accumulated during the 3 days of treatment, exhibiting a median half-life of 43.7&nbsp;hrs (range: 27.8-131&nbsp;hrs). In a separate study, pharmacokinetic measurements in 15 paediatric patients receiving oral idarubicin hydrochloride in doses ranging from 30 to 50&nbsp;mg/m<sup>2</sup> during the 3&nbsp;days of treatment, the maximum plasma concentration of idarubicin was 10.6&nbsp;ng/mL (range 2.7-16.7&nbsp;ng/mL at the 40&nbsp;mg/m<sup>2</sup> dose). The median terminal half-life of idarubicin of was 9.2&nbsp;hrs (range: 6.4-25.5&nbsp;hrs). Significant accumulation of idarubicinol was seen over the 3&nbsp;day treatment period. The observed terminal half-life value of idarubicin after i.v. was comparable to that following oral administration in paediatric patients.</p><p>&nbsp;</p><p>Since C<sub>max</sub> of idarubicin is similar in children and adults following oral administrations, absorption kinetics seem not to differ between adults and children.</p><p>&nbsp;</p><p>Following both oral and i.v. administrations, the elimination half-life values of idarubicin in children and adults differ.</p><p>&nbsp;</p><p>Total body clearance values of 30-107.9&nbsp;L/h/m<sup>2</sup> for idarubicin reported for adults are higher than the values of 18-33&nbsp;L/h/m<sup>2</sup> reported for paediatric populations. Although idarubicin has a very large volume of distribution in both adults and children, suggesting that much of the drug is bound to tissues, the shorter elimination half-life and lower total body clearance are not entirely explained by a smaller apparent volume of distribution in children compared to adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Idarubicin has mutagenic properties and it is carcinogenic in rats.</p><p>&nbsp;</p><p>Reproduction studies in animals have shown that idarubicin is embryotoxic and teratogenic in rats but not rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycerol</p><p>Water for injection</p><p>Hydrochloric acid, used for pH adjustment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prolonged contact of Zavedos with any solution of an alkaline pH should be avoided as it will result in degradation of the drug.</p><p>Zavedos should not be mixed with heparin as a precipitate may form.&nbsp; This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
3 years

Opened vial
Each vial is for single use only and should be used immediately after opening. If not used immediately, in use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Unopened vial:</em></strong><strong> </strong>Store and transport refrigerated (2&deg;C - 8&deg;C), Do not freeze, and protect from light.</p><p><strong><em>Opened vial:</em></strong><strong> </strong>From a microbiological point of view, unless the method of opening/dilution precludes the risk of microbial contamination, this medicinal product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.</p><p>&nbsp;</p><p>Keep the vial in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glass vials which are closed with a siliconised, halobutyl rubber stopper and sealed with an aluminium cap with a plastic flip off top.</p><p>Zavedos is available in 5 mL, and 10 mL vials packed singly in cartons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Preparation and precautions:</em></p><p>The following protective recommendations are given due to the toxic nature of this substance:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This product should be handled only by personnel who have been trained in the safe handling of such preparations.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant staff should be excluded from working with this drug.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personnel handling Zavedos should wear protective clothing: goggles, gowns and disposable gloves and masks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any work surfaces used should be protected by disposable, plastic-backed, absorbent paper.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution should not be allowed to contact mucous membranes, eyes or skin. Accidental contact with the skin and eyes should be treated immediately by copious lavage with water, or sodium bicarbonate solution, medical attention should be sought.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spillage or leakage should be treated with dilute sodium hypochlorite (1% available chlorine) solution, preferably by soaking, and then with water.</p><p>&nbsp;</p><p><em>Intravenous administration:</em></p><p>Administration ZAVEDOS for injection contains no antimicrobial preservative.&nbsp; Use in one patient on one occasion only.&nbsp; Discard any residue.</p><p>&nbsp;</p><p>ZAVEDOS for injection must be administrated only by the intravenous route and the reconstituted solution should be given via tubing of a freely running intravenous infusion of 0.9% Sodium Chloride Injection, taking 10-15 minutes over the injection.</p><p>&nbsp;</p><p>The tubing should be attached to a butterfly needle or other suitable device and inserted preferably into a large vein.&nbsp; This technique minimises the risk of thrombosis or perivenous extravasation, which can lead to severe cellulitis and necrosis.&nbsp; Venous sclerosis may result from injection into small veins or repeated injections in the same vein.</p><p>&nbsp;</p><p>Care in the administration of ZAVEDOS will reduce the chance of perivenous infiltration. It may also decrease the chance of local reactions such as urticaria and erythematous streaking.</p><p>&nbsp;</p><p>During intravenous administration of ZAVEDOS, extravasation may occur with or without an accompanying stinging or burning sensation, even if blood returns well on aspiration of the infusion needle.&nbsp; If any signs or symptoms of extravasation have occurred, the injection or infusion should be immediately terminated and restarted in another vein.&nbsp; If it is known or suspected that subcutaneous extravasation has occurred, it is recommended that intermittent ice packs (&frac12; hour immediately, then &frac12; hour 4 times per day for 3 days) be placed on the area of extravasation and that the affected extremity be elevated.</p><p>&nbsp;</p><p>In cases of extravasation dexrazoxane can be used to prevent or reduce tissue injury. If used, dexrazoxane should be administered in a large vein in an area away from the extravasation (i.e the opposite arm).</p><p>&nbsp;</p><p>Because of the progressive nature of extravasation reactions, the area of injection should be frequently examined and plastic surgery consultations obtained early if there is any sign of local reaction such as pain, erythema, oedema or vesication.&nbsp; If ulceration begins or there is persistent pain at the site of extravasation, early wide excision of the involved area should be considered.&rdquo;</p><p>&nbsp;</p><p><em>Disposal:</em></p><p>All items used for administration or cleaning, including gloves, should be placed in high risk, waste disposal bags for high temperature incineration.</p><p>&nbsp;</p><p>For single use only. Any unused solution should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Australia Pty LTD, 17 151 Clarence Street Sydney NSW 2000, Australia

MANUFACTURER
Zydus Hospira Oncology Private Limited (ZHOPL), India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2024	
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>